title: General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.
abstract: BACKGROUND
  Induction of cytochrome P450 (CYP) 3A4 potentially reduces the blood concentrations of substrate drugs to less than one-tenth, which results in ineffective pharmacotherapy. Although the prediction of drug-drug interactions (DDIs) that are mediated by induction of CYP3A4 has been performed mainly on the basis of in vitro information, such methods have met with limited success in terms of their accuracy and applicability. Therefore, a realistic method for the prediction of CYP3A4-mediated inductive DDIs is of major clinical importance.
  
  
  OBJECTIVE
  The objective of the present study was to construct a robust and accurate method for the prediction of CYP3A4-mediated inductive DDIs. Such a method was developed on the basis of the principle applied for prediction of inhibitory DDIs in a previous report. A unique character of this principle is that the extent of alterations in the area under the plasma concentration-time curve (AUC) is predicted on the basis of in vivo information from minimal clinical studies without using in vitro data.
  
  
  METHODS
  The analysis is based on 42 DDI studies in humans reported in 37 published articles over the period 1983-2007. Kinetic analysis revealed that the reduction in the AUC of a substrate of CYP3A4 produced by consecutive administration of an inducer of CYP3A4 could be approximated by the equation 1/(1 + CRCYP3A4 * ICCYP3A4), where CRCYP3A4 is the ratio of the apparent contribution of CYP3A4 to the oral clearance of a substrate and ICCYP3A4 is the apparent increase in clearance of a substrate produced by induction of CYP3A4. Using this equation, the ICCYP3A4 was calculated for seven inducers (bosentan, carbamazepine, efavirenz, phenytoin, pioglitazone, rifampicin [rifampin], and St John's wort [hypericum]) on the basis of the reduction in the AUC of a coadministered standard substrate of CYP3A4, such as simvastatin, in ten DDI studies. The CRCYP3A4 was calculated for 22 substrates on the basis of the previously reported method from inhibitory DDI studies using a potent CYP3A4 inhibitor such as itraconazole or ketoconazole.
  
  
  RESULTS
  The proposed method enabled the prediction of AUC reduction by CYP3A4 induction with any combination of these substrates and inducers (total 154 matches). To assess the accuracy of the prediction, the AUC reductions in 32 studies were analysed. We found that the magnitude of the deviation between the mean values of the observed and predicted AUCs of all substrate drugs was <20% of the AUCs of the respective substrate drugs before administration of the inducers. In addition, rifampicin was found to be the most potent inducer among the compounds analysed in the present study, with an ICCYP3A4 value of 7.7, followed by phenytoin and carbamazepine, with values of 4.7 and 3.0, respectively. The ICCYP3A4 values of the other CYP3A4 inducers analysed in the present study were approximately 1 or less, which suggests that the AUCs of coadministered drugs may not be reduced to less than approximately half, even if the drug is metabolized solely by CYP3A4.
  
  
  CONCLUSIONS
  By using the method reported in the present study, the susceptibilities of a substrate drug of CYP3A4 to inductive DDIs can be predicted quantitatively. It was indicated that coadministration of rifampicin, phenytoin and carbamazepine may reduce plasma AUCs to less than half for a broad range of CYP3A4 substrate drugs, with CRCYP3A4 values greater than 0.13, 0.21 and 0.33, respectively.
authors.affiliation: Department of Pharmacy, University of Tokyo Hospital, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Ohno
authors.forename: Akihiro
authors.initials: A
authors.lastname: Hisaka
authors.forename: Masaki
authors.initials: M
authors.lastname: Ueno
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Suzuki
mesh_terms: D000284:Administration, Oral; D019540:Area Under Curve; D051544:Cytochrome P-450 CYP3A / Q000096:biosynthesis*; D004347:Drug Interactions; D004790:Enzyme Induction; D006801:Humans; D008954:Models, Biological; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000378:metabolism*; D010599:Pharmacokinetics
chemical_list: D004364:Pharmaceutical Preparations; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human
references.citation: Antimicrob Agents Chemother. 2007 Oct;51(10):3617-26
references.pmid: 17646413
references.citation: J Pharmacol Exp Ther. 1997 Dec;283(3):1552-62
references.pmid: 9400033
references.citation: Am J Med. 2002 Dec 15;113(9):746-50
references.pmid: 12517365
references.citation: Drug Metab Dispos. 2006 Jan;34(1):166-75
references.pmid: 16221752
references.citation: Br J Clin Pharmacol. 2001 May;51(5):443-50
references.pmid: 11422002
references.citation: Clin Pharmacol Ther. 1999 Apr;65(4):428-38
references.pmid: 10223781
references.citation: Eur J Clin Pharmacol. 1996;51(3-4):331-4
references.pmid: 9010708
references.citation: Clin Pharmacokinet. 1998 Nov;35(5):361-90
references.pmid: 9839089
references.citation: Clin Pharmacol Ther. 1996 Jan;59(1):7-13
references.pmid: 8549036
references.citation: J Clin Pharm Ther. 2005 Jun;30(3):285-90
references.pmid: 15896247
references.citation: Drug Metab Dispos. 2006 Oct;34(10):1742-8
references.pmid: 16837568
references.citation: Mol Pharmacol. 1999 Dec;56(6):1329-39
references.pmid: 10570062
references.citation: Drug Metab Rev. 1997 Feb-May;29(1-2):413-580
references.pmid: 9187528
references.citation: J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):307-12
references.pmid: 15980690
references.citation: Pharmacogenetics. 1999 Dec;9(6):725-34
references.pmid: 10634135
references.citation: J Biol Chem. 2001 May 4;276(18):14581-7
references.pmid: 11297522
references.citation: Clin Pharmacokinet. 2007;46(2):133-57
references.pmid: 17253885
references.citation: J Clin Invest. 1999 Jul;104(2):147-53
references.pmid: 10411543
references.citation: Drug Metab Dispos. 2003 Jul;31(7):815-32
references.pmid: 12814957
references.citation: Drug Metab Dispos. 1999 Aug;27(8):887-94
references.pmid: 10421615
references.citation: Clin Pharmacol Ther. 2003 Jan;73(1):41-50
references.pmid: 12545142
references.citation: Clin Pharmacokinet. 2003;42(9):819-50
references.pmid: 12882588
references.citation: Pharmacotherapy. 1995 May-Jun;15(3):353-6
references.pmid: 7667170
references.citation: J Clin Invest. 1998 Sep 1;102(5):1016-23
references.pmid: 9727070
references.citation: Clin Pharmacokinet. 2005;44(3):279-304
references.pmid: 15762770
references.citation: Br J Clin Pharmacol. 1999 Nov;48(5):733-42
references.pmid: 10594476
references.citation: Clin Pharmacol Ther. 2007 Feb;81(2):194-204
references.pmid: 17192770
references.citation: Clin Pharmacol Ther. 2004 Oct;76(4):391
references.pmid: 15470340
references.citation: Eur J Clin Pharmacol. 2004 Feb;59(12):879-82
references.pmid: 14691614
references.citation: Clin Pharmacokinet. 2001;40(12):893-905
references.pmid: 11735608
references.citation: Br J Clin Pharmacol. 2000;49 Suppl 1:65S-70S
references.pmid: 10771457
references.citation: Eur J Pharm Sci. 2000 Nov;12(1):3-12
references.pmid: 11121729
references.citation: Br J Clin Pharmacol. 1989 Oct;28(4):373-87
references.pmid: 2590599
references.citation: Drug Metab Dispos. 1990 Sep-Oct;18(5):595-606
references.pmid: 1981707
references.citation: Drug Metab Dispos. 2005 Jun;33(6):764-70
references.pmid: 15764714
references.citation: Am J Obstet Gynecol. 1998 Feb;178(2):300-4
references.pmid: 9500490
references.citation: J Pharmacol Exp Ther. 2005 Feb;312(2):583-91
references.pmid: 15523003
references.citation: Drug Metab Dispos. 2006 Jul;34(7):1229-36
references.pmid: 16595711
references.citation: Eur J Clin Pharmacol. 2004 Aug;60(6):427-30
references.pmid: 15232663
references.citation: Clin Pharmacol Ther. 1992 Nov;52(5):453-7
references.pmid: 1424418
references.citation: Drug Metab Dispos. 1989 Mar-Apr;17(2):197-207
references.pmid: 2565211
references.citation: Drug Metab Dispos. 2005 Oct;33(10):1477-81
references.pmid: 16014768
references.citation: Drug Metab Dispos. 1996 Oct;24(10):1121-3
references.pmid: 8894514
references.citation: Br J Clin Pharmacol. 1984 Dec;18(6):887-93
references.pmid: 6529529
references.citation: J Pharm Sci. 1998 Nov;87(11):1322-30
references.pmid: 9811484
references.citation: Xenobiotica. 2007 Oct-Nov;37(10-11):1196-224
references.pmid: 17968743
references.citation: Br J Clin Pharmacol. 2003 Feb;55(2):203-11
references.pmid: 12580993
references.citation: Clin Pharmacol Ther. 2000 Dec;68(6):592-7
references.pmid: 11180018
references.citation: Clin Pharmacokinet. 2007;46(8):681-96
references.pmid: 17655375
references.citation: Clin Pharmacol Ther. 2005 Aug;78(2):154-67
references.pmid: 16084850
references.citation: Br J Clin Pharmacol. 2006 Jan;61(1):58-69
references.pmid: 16390352
references.citation: Clin Pharmacol Ther. 2001 Oct;70(4):317-26
references.pmid: 11673747
references.citation: Br J Clin Pharmacol. 2005 Nov;60(5):508-18
references.pmid: 16236041
references.citation: Cancer Chemother Pharmacol. 2004 Oct;54(4):290-4
references.pmid: 15138710
references.citation: Cancer Chemother Pharmacol. 2004 Feb;53(2):102-6
references.pmid: 14605865
references.citation: Drug Metab Dispos. 2001 Apr;29(4 Pt 1):443-52
references.pmid: 11259329
references.citation: Clin Pharmacol Ther. 1997 Jan;61(1):8-14
references.pmid: 9024169
references.citation: Drug Metab Pharmacokinet. 2005 Aug;20(4):236-43
references.pmid: 16141603
references.citation: Pharm Res. 1995 Sep;12(9):1304-10
references.pmid: 8570526
references.citation: Pharm Res. 2006 Jun;23(6):1089-116
references.pmid: 16718615
references.citation: Drug Metab Dispos. 2000 Apr;28(4):467-74
references.pmid: 10725316
references.citation: Eur J Clin Pharmacol. 2005 May;61(3):185-8
references.pmid: 15776275
references.citation: Clin Pharmacokinet. 2000 Feb;38(2):111-80
references.pmid: 10709776
references.citation: Pharmacol Toxicol. 1999 Feb;84(2):94-7
references.pmid: 10068153
references.citation: Eur J Clin Pharmacol. 2000 Apr;56(1):57-60
references.pmid: 10853878
references.citation: Eur J Pharm Sci. 2000 Sep;11(3):185-9
references.pmid: 11042223
references.citation: Br J Clin Pharmacol. 1997 Aug;44(2):190-4
references.pmid: 9278209
references.citation: J Clin Pharmacol. 1998 Feb;38(2):112-21
references.pmid: 9549641
references.citation: J Clin Psychopharmacol. 2002 Feb;22(1):46-54
references.pmid: 11799342
references.citation: J Pharm Pharmacol. 2000 Oct;52(10):1265-9
references.pmid: 11092571
references.citation: Obstet Gynecol. 2001 Aug;98(2):218-23
references.pmid: 11506836
references.citation: J Clin Psychopharmacol. 2001 Feb;21(1):89-93
references.pmid: 11199955
references.citation: Br J Clin Pharmacol. 2005 Feb;59(2):199-206
references.pmid: 15676042
references.citation: Kidney Int. 2000 Jan;57(1):224-31
references.pmid: 10620203
references.citation: Pharmacotherapy. 1998 Jan-Feb;18(1):84-112
references.pmid: 9469685
references.citation: Br Med J (Clin Res Ed). 1983 Mar 19;286(6369):923-5
references.pmid: 6403136
references.citation: JAMA. 2003 Sep 17;290(11):1500-4
references.pmid: 13129991
references.citation: Clin Pharmacol Ther. 1997 Dec;62(6):629-34
references.pmid: 9433391
references.citation: Chem Biol Interact. 1997 Nov 6;107(1-2):17-30
references.pmid: 9402947
references.citation: Clin Pharmacol Ther. 2004 Oct;76(4):330-40
references.pmid: 15470332
references.citation: Clin Pharmacokinet. 2005;44(10):1067-81
references.pmid: 16176119
references.citation: Clin Pharmacokinet. 2003;42(3):293-301
references.pmid: 12603176
references.citation: Blood. 2004 Aug 15;104(4):1229-30
references.pmid: 15294859
references.citation: Clin Pharmacol Ther. 2000 Oct;68(4):345-55
references.pmid: 11061574
references.citation: Br J Clin Pharmacol. 1997 May;43(5):471-4
references.pmid: 9159561
references.citation: Clin Pharmacol Ther. 2006 Aug;80(2):126-35
references.pmid: 16890574
references.citation: Clin Pharmacokinet. 2005;44(9):915-34
references.pmid: 16122280
references.citation: Br J Clin Pharmacol. 2006 Nov;62(5):512-26
references.pmid: 17010103
references.citation: Life Sci. 1990;47(22):1981-8
references.pmid: 2273938
references.citation: Drug Metab Dispos. 2005 Jun;33(6):837-44
references.pmid: 15897600
references.citation: Clin Pharmacol Ther. 2001 Mar;69(3):114-21
references.pmid: 11240975
references.citation: Clin Pharmacol Ther. 2006 Apr;79(4):350-61
references.pmid: 16580903
references.citation: Neuropsychopharmacology. 1998 May;18(5):364-9
references.pmid: 9536449
references.citation: Clin Pharmacol Ther. 2003 Dec;74(6):525-35
references.pmid: 14663455